Skip to content
Skip to navigation menu


Pulmonary delivery of anti-microbial peptides (AMP’s): disposition within ex-vivo and in-vivo lung models


Mark Gumbleton and Research Fellow Dr Chris Morris are extending their collaboration with dstl (Defence Science and Technology Laboratory) to further develop anti-microbial peptides (AMP) for delivery to the lung.

Aims of Project

To assess the tissue distribution of AMPs delivered to intact lung models and to evaluate changes in the profile of pulmonary cytokines and enzymes in response to AMP delivery. the project will involve the study of AMP pharmacokinetics upon the delivery of nanoÿ and microparticulate AMP formulations to ex-vivo and in-vivo lung models.


Defence Science and Technology Laboratory

Project Value



1 year

Prof Mark Gumbleton

Position:Professor of Experimental Therapeutics and Director of Research
Staff picture of Prof Mark Gumbleton
Telephone: +44 (0)29 208 75449